Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA

July 1, 2022

Novavax is awaiting US emergency use authorization for our prototype COVID-19 vaccine and we are committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype vaccine offers broad immune responses including against circulating variants, such as the Omicron BA.4/5. 

Novavax is already well underway in our variant program and will accelerate our focus on Omicron BA.4/5, as recommended by FDA in their guidance on June 30th.  We expect to have additional preclinical data on Omicron BA.4/5 in the late summer or fall, and expect to be in a position to provide an Omicron-containing vaccine in Q4 of this year.  

Novavax continues to believe in the importance of vaccines that offer broad immune responses against a variety of variants, given the fact that COVID-19 will continue to evolve.